Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Decline in prenatal buprenorphine/naloxone fills during the COVID-19 pandemic in the United States

View ORCID ProfileAshley L. O’Donoghue, Alyse Reichheld, Timothy S. Anderson, Chloe A. Zera, Tenzin Dechen, Jennifer P. Stevens
doi: https://doi.org/10.1101/2021.10.08.21264760
Ashley L. O’Donoghue
1Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ashley L. O’Donoghue
  • For correspondence: aodonogh@bidmc.harvard.edu
Alyse Reichheld
1Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center, Boston, MA
2Tufts University School of Medicine, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy S. Anderson
1Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center, Boston, MA
3Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chloe A. Zera
4Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Beth Israel Deaconess Medical Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tenzin Dechen
1Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer P. Stevens
1Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center, Boston, MA
5Division for Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background and Aims Pregnancy provides a critical opportunity to engage women with substance use disorder in care. Buprenorphine/naloxone treatment is associated with improved pregnancy and fetal outcomes, but prior to the COVID-19 pandemic, there were multiple barriers to accessing buprenorphine/naloxone during pregnancy. Care disruptions during the pandemic may have further exacerbated these already existing barriers. To quantify these changes, we examined trends in the number of individuals filling prescriptions for prenatal buprenorphine/naloxone prescriptions during the COVID-19 pandemic.

Methods We estimated an interrupted time series model using linked national pharmacy claims and medical claims data from May 2019 to December 2020. We estimated changes in the level and trend in the monthly number of individuals filling prescriptions for prenatal buprenorphine/naloxone during the COVID-19 pandemic. We then stratified our analyses by payer.

Results We identified 2,947 pregnant patients filling buprenorphine/naloxone prescriptions. Before the pandemic, there was positive growth in the monthly number of individuals filling prescriptions for prenatal buprenorphine/naloxone (4.83% (95% confidence interval (CI): 3.40% to 6.26%). During the pandemic, the monthly growth rate in individuals filling prescriptions for prenatal buprenorphine/naloxone declined for both patients on commercial insurance and patients on Medicaid (all payers: -5.53% (95% CI: -7.28% to -3.78%); Medicaid: -7.66% (95% CI: -10.42% to -4.90%); Commercial: -3.59% (95% CI: -5.53% to -1.66%)).

Conclusion The number of pregnant individuals filling buprenorphine/naloxone prescriptions was increasing prior to the pandemic, but this growth has been lost during the pandemic.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

O'Donoghue, Dechen, and Stevens are funded by an unrestricted philanthropic gift from Google.org. Google.org had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval, of the manuscript; and decision to submit the manuscript for publication.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This research used only deidentified data and was classified as exempt from written informed consent by the Beth Israel Deaconess Medical Center institutional review board.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data, technology, and services used in the generation of these research findings are restricted access and were generously supplied pro bono by the COVID-19 Research Database partners. Applications for access can be found at the following URL: https://covid19researchdatabase.org/.

https://covid19researchdatabase.org/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted October 11, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Decline in prenatal buprenorphine/naloxone fills during the COVID-19 pandemic in the United States
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Decline in prenatal buprenorphine/naloxone fills during the COVID-19 pandemic in the United States
Ashley L. O’Donoghue, Alyse Reichheld, Timothy S. Anderson, Chloe A. Zera, Tenzin Dechen, Jennifer P. Stevens
medRxiv 2021.10.08.21264760; doi: https://doi.org/10.1101/2021.10.08.21264760
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Decline in prenatal buprenorphine/naloxone fills during the COVID-19 pandemic in the United States
Ashley L. O’Donoghue, Alyse Reichheld, Timothy S. Anderson, Chloe A. Zera, Tenzin Dechen, Jennifer P. Stevens
medRxiv 2021.10.08.21264760; doi: https://doi.org/10.1101/2021.10.08.21264760

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Addiction Medicine
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1256)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (537)
  • Epidemiology (10047)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2481)
  • Geriatric Medicine (239)
  • Health Economics (482)
  • Health Informatics (1652)
  • Health Policy (756)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11888)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2301)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1257)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2294)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (654)
  • Rheumatology (288)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (271)
  • Toxicology (44)
  • Transplantation (130)
  • Urology (100)